Interactions of Tofacitinib and Dexamethasone on Lymphocyte Proliferation

[1]  H. Sasano,et al.  Significance of glucocorticoid signaling in triple-negative breast cancer patients: a newly revealed interaction with androgen signaling , 2020, Breast Cancer Research and Treatment.

[2]  D. DuBois,et al.  Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats , 2019, The AAPS Journal.

[3]  D. DuBois,et al.  Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part II: Sex Differences in Methylprednisolone Pharmacokinetics and Corticosterone Suppression , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[4]  D. DuBois,et al.  Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part III: Estrous Cycle and Estrogen Receptor–Dependent Antagonism of Glucocorticoid-Induced Leucine Zipper (GILZ) Enhancement by Corticosteroids , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[5]  W. Ouyang,et al.  Exposure-Effect Relationships in Established Rat Adjuvant-Induced and Collagen-Induced Arthritis: A Translational Pharmacokinetic-Pharmacodynamic Analysis , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[6]  D. DuBois,et al.  Modeling Sex Differences in Anti-inflammatory Effects of Dexamethasone in Arthritic Rats , 2018, Pharmaceutical Research.

[7]  D. DuBois,et al.  Modeling Combined Immunosuppressive and Anti-inflammatory Effects of Dexamethasone and Naproxen in Rats Predicts the Steroid-Sparing Potential of Naproxen , 2017, Drug Metabolism and Disposition.

[8]  G. Burmester,et al.  Novel treatment strategies in rheumatoid arthritis , 2017, The Lancet.

[9]  Guimin Zhang,et al.  Cycloastragenol mediates activation and proliferation suppression in concanavalin A-induced mouse lymphocyte pan-activation model , 2017, Immunopharmacology and immunotoxicology.

[10]  J. Kremer,et al.  Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies , 2016, International journal of rheumatic diseases.

[11]  J. D. Clark,et al.  The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. , 2016, Clinical and experimental rheumatology.

[12]  M. Schmitt,et al.  Standardization of cryopreserved peripheral blood mononuclear cells through a resting process for clinical immunomonitoring—Development of an algorithm , 2016, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[13]  T. Michalak,et al.  Immune cell subsets and their gene expression profiles from human PBMC isolated by Vacutainer Cell Preparation Tube (CPT™) and standard density gradient , 2015, BMC Immunology.

[14]  Ping Zhang,et al.  Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy , 2015, BMC Immunology.

[15]  M. Dowty,et al.  Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[16]  D. Mayer,et al.  Interaction of JAK with steroid receptor function , 2013, JAK-STAT.

[17]  Yoshiya Tanaka,et al.  JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical , 2013, Modern rheumatology.

[18]  Yoshiya Tanaka,et al.  The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells. , 2012, Arthritis and rheumatism.

[19]  N. Olsen,et al.  Sexual dimorphism of RA manifestations: genes, hormones and behavior , 2011, Nature Reviews Rheumatology.

[20]  K. Chapman,et al.  The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights , 2011, Molecular and Cellular Endocrinology.

[21]  D. Morris,et al.  Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis , 2010, Journal of Inflammation.

[22]  Richard W. Lee,et al.  The Effects of Cytokines on Suppression of Lymphocyte Proliferation by Dexamethasone1 , 2009, The Journal of Immunology.

[23]  R. Vollenhoven.  Sex differences in rheumatoid arthritis: more than meets the eye... , 2009 .

[24]  J. Morales-Montor,et al.  Immune sexual dimorphism: Effect of gonadal steroids on the expression of cytokines, sex steroid receptors, and lymphocyte proliferation , 2009, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  J. O’Shea,et al.  Therapeutic targeting of Janus kinases , 2008, Immunological reviews.

[26]  R. Curi,et al.  Regulation of interleukin-2 signaling by fatty acids in human lymphocytes Published, JLR Papers in Press, June 25, 2007. , 2007, Journal of Lipid Research.

[27]  H. Weedon,et al.  Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis , 2005, Annals of the rheumatic diseases.

[28]  William J Jusko,et al.  Pharmacodynamic interaction of recombinant human interleukin-10 and prednisolone using in vitro whole blood lymphocyte proliferation. , 2002, Journal of pharmaceutical sciences.

[29]  S. Jordan,et al.  Antithrombin III inhibits lymphocyte proliferation, immunoglobulin production and mRNA expression of lymphocyte growth factors (IL-2, gamma-IFN and IL-4) in vitro. , 2001, Transplant immunology.

[30]  David E. Levy,et al.  STAT1 Affects Lymphocyte Survival and Proliferation Partially Independent of Its Role Downstream of IFN-γ1 , 2000, The Journal of Immunology.

[31]  U. Feige,et al.  Dexamethasone enhances CTLA-4 expression during T cell activation , 1999, Cellular and Molecular Life Sciences CMLS.

[32]  W. Jusko,et al.  Species- and gender-related differences in cyclosporine/prednisolone/sirolimus interactions in whole blood lymphocyte proliferation assays. , 1998, The Journal of pharmacology and experimental therapeutics.

[33]  P. Musiani,et al.  IL-10 synergizes with dexamethasone in inhibiting human T cell proliferation. , 1998, The Journal of pharmacology and experimental therapeutics.

[34]  F. Andris,et al.  Dexamethasone inhibits the early steps of antigen receptor signaling in activated T lymphocytes. , 1996, Journal of immunology.

[35]  James M. Roberts,et al.  lnterleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin , 1994, Nature.

[36]  J. Roberts,et al.  Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes , 1994, Molecular and cellular biology.

[37]  E. Cundari,et al.  Analysis of susceptibility of mature human T lymphocytes to dexamethasone‐induced apoptosis , 1994, European journal of immunology.

[38]  J. Dwyer,et al.  The use of concanavalin A to study the immunoregulation of human T cells. , 1981, Clinical and experimental immunology.

[39]  J. Hadden,et al.  Effects of concanavalin A and a succinylated derivative on lymphocyte proliferation and cyclic nucleotide levels. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Mihara,et al.  Kinetics of lymphocyte proliferation in the immune response. , 1966, Archivum histologicum Japonicum = Nihon soshikigaku kiroku.

[41]  W. Paul.  Interleukin 4: signalling mechanisms and control of T cell differentiation. , 1997, Ciba Foundation symposium.

[42]  James M. Roberts,et al.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. , 1994, Genes & development.